Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, randomized, double-blind, parallel, pharmacokinetic study of subcutaneous and intramuscular lanreotide in healthy volunteers.

Next Previous
Search
Trial Profile

A phase 1, randomized, double-blind, parallel, pharmacokinetic study of subcutaneous and intramuscular lanreotide in healthy volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary) ; Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Pharmacokinetics

    • Most Recent Events

    • 30 Sep 2016 According to an Ipsen Biopharmaceuticals media release, data from this study were presented at the annual symposium of the North American Neuroendocrine Tumor Society (NANETS).
    • 27 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top